| Zacks Company Profile for Avid Bioservices, Inc. (CDMO : NSDQ) |
|
|
| |
| • Company Description |
| Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It also offer process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. Avid Bioservices Inc., formerly known as Peregrine Pharmaceuticals Inc., is based in TUSTIN, United States.
Number of Employees: 327 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $18.76 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 897,119 shares |
| Shares Outstanding: 62.55 (millions) |
| Market Capitalization: $1,173.38 (millions) |
| Beta: 1.76 |
| 52 Week High: $21.81 |
| 52 Week Low: $11.30 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
14.53% |
10.96% |
| 12 Week |
33.05% |
23.30% |
| Year To Date |
36.24% |
25.21% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
14191 Myford Road
-
Tustin,CA 92780
USA |
ph: 714-508-6100
fax: 714-838-5817 |
sdiaz@vidasp.com |
http://www.avidbio.com |
|
|
| |
| • General Corporate Information |
Officers
Nicholas S. Green - President; Chief Executive Officer and Director
Joseph Carleone - Chairman of the Board of Directors
Daniel R. Hart - Chief Financial Officer
Esther M. Alegria - Director
Richard B. Hancock - Director
|
|
Peer Information
Avid Bioservices, Inc. (CORR.)
Avid Bioservices, Inc. (RSPI)
Avid Bioservices, Inc. (CGXP)
Avid Bioservices, Inc. (BGEN)
Avid Bioservices, Inc. (GTBP)
Avid Bioservices, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 05368M106
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: April
Last Reported Quarter: 01/01/23
Next Expected EPS Date: 07/05/23
|
|
Share - Related Items
Shares Outstanding: 62.55
Most Recent Split Date: 7.00 (0.14:1)
Beta: 1.76
Market Capitalization: $1,173.38 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.02 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.04 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/05/23 |
|
|
|
| |
